Rates of Routine Cancer Screening, Diagnosis Before vs After Pandemic

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, NOVEMBER 17, 2022

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2022.5481?guestAccessKey=a155d93d-a9e8-4b05-b0be-66f75cffca20&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111722

 

About The Study: In this cross-sectional study of data from January 2017 to December 2021, population-based screening and diagnosis remained below pre-pandemic levels for breast, cervical and colorectal cancer. The findings suggest that screening quickly rebounded after the initial stages of the pandemic; however, the longer follow-up time reveals that gaps in preventive cancer screening returned and worsened. 

Authors: Allison H. Oakes, Ph.D., of Trilliant Health in Brentwood, Tennessee, is the corresponding author. 

 

(doi:10.1001/jamaoncol.2022.5481)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.